Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N1 vaccine AF03 adjuvanted
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
H5N1 vaccine AF03 adjuvanted is an inactivated split-virion influenza A(H5N1) vaccine formulated with Sanofi’s AF03 oil-in-water emulsion adjuvant to enhance and broaden immune responses against avian H5N1 strains while enabling antigen dose sparing. The AF03 adjuvant contains squalene with surfactants such as sorbitan oleate and polyoxyethylene cetostearyl ether in an aqueous phase with mannitol, and is mixed with low-dose hemagglutinin antigen from H5N1 strains such as A/Indonesia/5/2005 in a two-vial presentation before intramuscular injection.[7][8] AF03 enhances antigen presentation and promotes strong humoral responses, increasing seroconversion and seroprotection rates at reduced HA doses compared with non-adjuvanted formulations, and has been evaluated in adult phase 2 clinical trials for pandemic preparedness.[2][8]
- Other names
- pandemic influenza A(H5N1) split virion vaccine AF03 adjuvantedinactivated split-virion H5N1 influenza vaccine AF03 adjuvanted
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on H5N1 vaccine AF03 adjuvanted.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N1 vaccine AF03 adjuvanted.